The translocator protein (TSPO) is prodromal to mitophagy loss in neurotoxicity

Area of Science:

• Neuroscience
• Cell Biology
• Mitochondrial Biology

Background:

• Mitochondrial dysfunction is a hallmark of Parkinson's Disease (PD).
• Identifying etiological factors impacting mitochondrial homeostasis is crucial for PD diagnosis and treatment, particularly for idiopathic forms.
• The 18 kDa Translocator Protein (TSPO) is investigated as a potential contributor to PD pathogenesis.

Purpose of the Study:

• To investigate the role of 18 kDa Translocator Protein (TSPO) in Parkinson's Disease pathogenesis.
• To elucidate the mechanisms by which TSPO influences mitochondrial function and cellular stress in response to neurotoxins.

Main Methods:

• In vitro and in vivo experiments using neurotoxins that mimic PD phenotypes.
• Analysis of TSPO expression levels and its impact on cellular redox-stress, cell death, and mitophagy.
• Investigation of TSPO's effect on extracellular signal-regulated protein kinase 1 and 2 (ERK1/2) signaling, transcription factor EB (TFEB), and lysosome production.
• Examination of genetic variances in the transcriptome to confirm TSPO's role in the autophagy-lysosomal pathway.

Main Results:

• Neurotoxins that mimic PD increase TSPO levels.
• Elevated TSPO enhances cellular redox-stress, dopamine-induced cell death susceptibility, and represses ubiquitin-dependent mitophagy.
• TSPO amplifies ERK1/2 signaling, leading to TFEB repression and impaired lysosome production.
• Transcriptome data confirms TSPO's necessity in altering the autophagy-lysosomal pathway during neurotoxicity.

Conclusions:

• 18 kDa Translocator Protein (TSPO) plays a significant role in Parkinson's Disease neurotoxicity.
• TSPO disrupts mitochondrial homeostasis by affecting redox-stress, mitophagy, and lysosome production via the ERK1/2-TFEB pathway.
• Targeting TSPO may offer a therapeutic strategy for Parkinson's Disease, especially idiopathic forms.